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Projected increases in the prevalence of both diabetes mellitus (DM) and osteoarthritis (OA) ensure
their common co-existence. In an era of increasing attention to personalized medicine, understanding
the inﬂuence of common comorbidities such as DM should result in improved care of patients with
OA. In this narrative review, we summarize the literature addressing the interactions between DM
and OA spanning the years from 1962 to 2014. We separated studies depending on whether they
investigated clinical populations, animal models, or cells and tissues. The clinical literature
addressing the inﬂuence of DM on OA and its therapeutic outcomes suggests that DM may augment
the development and severity of OA and that DM increases risks associated with joint replacement
surgery. The few high quality studies using animal models also support an adverse effect of DM on
OA. We review strengths and weaknesses of the common rodent models of DM. The heterogeneous
literature derived from studies of articular cells and tissues also supports the existence of biochemical
and biomechanical changes in articular tissues in DM, and begins to characterize molecular mech-
anisms activated in diabetic-like environs which may contribute to OA. Increasing evidence from the
clinic and the laboratory supports an adverse effect of DM on the development, severity, and ther-
apeutic outcomes for OA. To understand the mechanisms through which DM contributes to OA,
further studies are clearly necessary. Future studies of DM-inﬂuenced mechanisms may shed light on
general mechanisms of OA pathogenesis and result in more speciﬁc and effective therapies for all OA
patients.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Diabetes mellitus (DM) and osteoarthritis (OA) are common
diseases that are predicted to increase in prevalence in the US and
worldwide1,2. Because of the resultant rise in the coexistence of
these two diseases and a burgeoning body of evidence suggesting
that DMmay adversely affect articular tissues and exacerbate OA, itj.joca.2015.01.013, http://dx.doi.org
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ternational. Published by Elsevier Lseems an opportune time to review literature in this area and
consider ways inwhich these diseases interact. The ultimate goal of
this ﬁeld of study is to understand OA in the diabetic patient in
order to individualize therapies and prognosis for patients having
both of these common diseases.
DM is deﬁned by metabolic abnormalities resulting from
dysfunction in the glucose-handling machinery of the body. It/10.1016/j.joca.2015.03.030.
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reduction in quantities of insulin which regulates glucose meta-
bolism. It is themost common form of DM in children andmay have
an autoimmune or post-infectious etiology. Although type 2 DM
(T2DM) may occur in children, it comprises the vast majority of
adult-onset DM. T2DM typically involves insulin resistance at the
cellular level. The metabolic abnormalities of DM are shared by all
forms of the disease; effective reduction of insulin activity causes
prolonged hyperglycemia which leads to osmotic and oxidative
stress and results in damage to the kidneys, eyes, nerves, and other
tissues. By the year 2035, the number of adults with DMworldwide
is estimated to be 592 million1.
Like DM, OA is also rising in prevalence and affects millions2.
It is typically deﬁned as a degenerative articular process char-
acterized by eroded articular cartilage, altered subchondral and
peri-cartilagenous bone, mild to moderate synovial inﬂamma-
tion, and pain. While cartilage damage is the ﬁnal common
endpoint in OA, primary abnormalities of other tissues such as
tendon, bone, or muscle may contribute to or even cause OA. DM,
especially T2DM, and OA share many epidemiologic features.
They are both complex diseases with considerable clinical het-
erogeneity and multifactorial etiologies involving interactions of
genetic and environmental factors. They also share common risk
factors. Aging is a risk factor for both T2DM and OA. The preva-
lence in the US of DM is 3.3/1000 among individuals aged 18e44,
and rises to 15.4/1000 for ages 65e793. Similarly, OA dramatically
increases with age, affecting 13.5% of adults 25 years and older
and 33.6% of those over the age of 654. Another important risk
factor for both diseases is obesity. The association of OA with
obesity is well-supported5, and obesity occurs in the majority of
people with T2DM6.
OA and DM frequently co-exist simply by chance due to their
high prevalence and shared risk factors. Nearly half (47.3%) of pa-
tients with DM have some form of arthritis7. The presence of co-
morbid conditions typically increases the care needs of individual
patients, decreases the effectiveness of care, and escalates health-
erelated costs. In addition, therapeutic strategies that emphasize
personalized medicine and take into account co-morbid conditions
may result in improved outcomes for patients with OA8. The
development of OAmay also complicate DM.While not the focus of
this review, there is increasing evidence that OA adds to the burden
of cardiovascular disease, which is higher than average in DM
patients9.
For this narrative review, we have searched the literature using
combinations of the following key words: “osteoarthritis”, “dia-
betes”, “hyperglycemia”, “articular cartilage”, “bone”, “tendon”
and “ligament”. We critically assess the literature exploring the
effects of DM on both OA and its management strategies. The few
clinical studies addressing this issue strongly support an associ-
ation between DM and OA. While animal studies are also quite
sparse and suffer from some methodological weaknesses, they
also suggest that DM may accelerate OA progression. Further,
current evidence derived from basic science studies suggests that
DM may adversely affect the homeostasis and repair of articular
tissues. These research studies give credibility to the hypothesis
that DM has clinically relevant effects on OA and warrant further
study.
Clinical studies
Population-based studies of DM and OA
There are only a handful of studies that directly address the
effects of DM on OA. Two cross-sectional population-based studiesusing questionnaires found that DM was signiﬁcantly more com-
mon in an OA cohort than a noneOA cohort10,11. In contrast, another
study found no increase in DM among OA patients; however, the
study subjects' healthier lifestyle may have inﬂuenced the results12.
The observation that speciﬁc features of OA may be more common
with DM e such as increased enthesophytes or more severe carti-
lage degeneration e supports an interaction between these
diseases13,14.
Multiple studies have used rates of arthroplasty as a surro-
gate for OA severity in examining the role of DM in OA. In a
cohort of patients undergoing arthroplasty for OA, no rela-
tionship was found between T2DM and bilateral OA or gener-
alized OA after adjustment for age, sex, BMI, and other
confounders for OA15. However, the study design based on
cohort analysis of arthroplasty patients limits the conclusions.
This is due to two issues; 1) a bias effect since OA severe enough
to require arthroplasty eliminates potential study subjects with
early stage OA, and 2) a survivor effect since uncontrolled dia-
betes may have been a cause to deter study subjects from
arthroplasty.
To avoid these effects, two more recent studies examine a
cohort of DM patients with non-DM patients as control16,17. The
ﬁrst study used the Veterans Affairs Health Administration
(VHA) national administrative database, and DM was deﬁned as
having two DM-related in- or out-patient visits or being pre-
scribed anti-diabetic medication16. The cohorts included 450,000
with DM and over 3 million without DM. Rates of total joint
arthroplasty were increased in patients with DM. The statisti-
cally signiﬁcant odds ratios ranged from 1.2 (primary total knee)
to 3.4 (revision total hip). When these data were stratiﬁed by
age, the highest risk ratios for each joint were found in the
youngest age group studied (46e55 years of age). The major
advantage of this study was its size, while the major disadvan-
tage was that data on body mass index (BMI) were not available.
Overall, if one uses arthroplasty as a surrogate for severe OA, this
study suggests that DM has a negative effect on OA by either
increasing its prevalence or by increasing the rate of
progression16.
A similar but smaller study17, analyzed retrospective data from
a prospective study with data collected over 20 years from a
regional hospital in Northern Italy. Of the 927 subjects that began
the prospective study, 69 met criteria for T2DM, deﬁned as having
a fasting blood glucose level over 126 mg/dL or a clinical diagnosis
with use of anti-DM medication. The authors found a signiﬁcant
and positive association of DMwith arthroplasty; relative risk was
about two and remained signiﬁcant in models that controlled for
age, sex, and BMI. Using a subset of the same population (347 total,
43 with T2DM), the authors found worse functional measures in
the T2DM group. In particular, the pain variable was signiﬁcantly
higher in both the KOOS (Knee Injury and Osteoarthritis Outcome
Score) and the WOMAC (Western Ontario and McMaster Univer-
sities Osteoarthritis Index) questionnaires. In addition, knee sy-
novitis was signiﬁcantly more common in people with DM. The
major advantages of this study were that known risk factors for
OA, particularly BMI, were controlled in the statistical models and
that the characteristics of OA (pain, function, and synovitis) were
further probed. The disadvantage of this study was its small
population size.
Despite the differences in approach, these two population-
based studies both found that DM doubles the risk for arthro-
plasty16,17. The VHA database was large enough to determine that
persons with DM have arthroplasty at younger ages16; while the
smaller single hospital study identiﬁed that the hazard risk asso-
ciated with DM remained after adjustment for other predictors for
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OA, and additional clinical studies comparing individual outcome
measures such as pain, function, or structural damage will be
necessary in the future.
Other clinical studies of DM and OA
Several recent studies began to approach the role of DM in
contributing to important outcome measures in OA, including OA
progression and pain. The effect of DM on OA progression was
recently studied in a cohort of 559 subjects with well-
characterized knee OA18. At baseline, 6.6% of the participants
had T2DM. In men with T2DM, annualized joint space narrowing
was statistically signiﬁcantly higher than in non-diabetic men
matched for BMI, age, hypertension and dyslipidemia. Of all the
components of the metabolic syndrome, only DM was identiﬁed
as an independent risk factor for knee OA progression. In a study
of 530 subjects with radiographic hand OA, primary analysis
showed no clear association between pain and DM19. Subset
analysis, however, showed higher pain scores in patients with DM
who had erosive OA deﬁned as radiographic evidence of more
than one IP joint with erosions. The impact of these conclusions is
uncertain since the ﬁeld does not have standard classiﬁcation
criteria for erosive OA. Certainly, further validation of these ﬁnd-
ings in OA is warranted.
Effect of DM on OA clinical care
The impact of DM on clinical care has been studied
frequently, with particular attention paid to the effects of DM
on arthroplasty outcomes. Arthroplasty patients with DM
sampled from the Nationwide Inpatient Sample database have
increased postsurgical death20,21. In contrast, older patients in
the Medicare database had no increased risk of postsurgical
death with DM22,23. Several studies have identiﬁed decreased
functional outcomes for arthroplasty performed on patients
with DM24,25. The most commonly reported DM-associated
complication is the increased rate of infection21,22,25e29. DM
may also increase the need for revision arthroplasty25,30,31.
Some arthroplasty outcomes may pertain to metabolic effects
on joint tissues such as defective bone healing, while others
reﬂect general risks of DM associated with major surgical pro-
cedures. All of these effects can add considerable cost to clinical
care20,21,32.
Effect of DM on human articular tissues
Studies of tissues from patients demonstrate that changes
capable of promoting OA occur in articular tissues in patients with
DM. For example, ankle cartilage from DM patients was softer with
lower stiffness indices and larger permeability parameters than
cartilage from non-diabetic patients33. Despite the limitations of
this study e including the use of frozen tissues, the focus on a joint
infrequently involved in OA, and the signiﬁcant age difference of
control subjects e the observed changes in biomechanical prop-
erties of articular cartilage might contribute to the development of
OA. Advanced glycation endproducts (AGE) may accumulate pre-
maturely in diabetic tissues and affect biomechanics34e37. A single,
small study using human tissue showed increased levels of the AGE
pentosidine in bone from patients with DM at the time of joint
replacement, but no signiﬁcant changes in pentosidine levels in
cartilage38. Tendon abnormalities may also contribute to OA. DMpatients demonstrate biochemical and biomechanical changes in
tendons that include decreased rupture threshold and disordered
collagen ﬁbrils39. There is also mounting evidence that bone heal-
ing is defective in DM patients40e46. Increased rates of non-healing
microfractures in patients with DM may alter bone mechanics and
promote OA, and they may also contribute to poor arthroplasty
outcomes. Multiple clinical studies demonstrate increased fracture
risk in post-menopausal women with T2DM which is not simply
linked to low bone mineral density on clinical densitometry41,42.
This paradox may be explained by changes in bone micro-
architecture, including increased cortical porosity43, excess
mineralization, and reduced subchondral bone heterogeneity44
with DM. Patients with DM have reduced serum biomarkers of
bone turnover as well as elevated sclerostin levels45,46. Such
changes could lead to increased bone stiffness which could accel-
erate OA.Animal studies
The presence of multiple comorbidities and other inherent
challenges in designing clinical studies to delineate mechanisms
responsible for increased OA in DM patients have logically led to
the use of animal models of these diseases. While primate and
rabbit models of DM have been described47e49, rodents are most
commonly used to replicate human DM50,51. Very few studies
directly address the severity or progression of OA in diabetic
animals.Animal models of T1DM
In T1DM, insulin production is absent or signiﬁcantly
impaired52. Genetic models of T1DM such as the Akita mouse
(C57BL/6-Ins2Akita) are available on several background strains53,54.
A non-genetic and very common method of modeling T1DM is to
chemically damage the pancreatic islets with single or multiple
dose regimens of streptozotocin (STZ)55e57. There are a few rat
models of T1DM including the LEW.1AR1/-iddm50 and the BBDP
rat58 both of which involve spontaneous autoimmune pancreatic
damage.Animal models of T2DM
In order to model human T2DM, the animal should have
hyperglycemia non-fasting blood glucose >250 mg/dL50,51,59,60,
insulin insensitivity, and preferably additional characteristics
such as polyuria and polydipsia49,50. Further information on
protocols for characterizing DM in rodents can be found in the
literature61,62. However, as with models of T1DM, no mouse
model perfectly mirrors human T2DM disease. The relative
contributions of obesity to acceleration of OA in DM are
particularly important in T2DM and its models. While isolating
the biomechanical effects of obesity from the effects of DM is
itself a challenge, in addition, obesity has well-known metabolic
consequences that add further complexity to the situation.
These include increased production of inﬂammatory cytokines
such as IL-1, TNFa, and adipokines (e.g., adiponectin, leptin, and
resistin)63 that promote inﬂammation and may accelerate OA.
Because obesity and T2DM almost always co-exist in human
T2DM, animal studies may be particularly useful in separating
the pathological contributions derived from these different
mechanisms.
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(DIO) which attempts to simulate human obesity-induced T2DM
but often results in only modestly increased glucose levels51,64e66.
The db/db mouse, ob/ob mouse, and fa/fa rat have monogenetic
defects that disrupt leptin signaling resulting in hyperphagia and
morbid obesity67. This leptin signaling defect is rare in human
T2DM60,64,67, and T2DM models created using polygenic mutations
are better models of human T2DM. The KK.Cg-Ay/J mouse was
developed by crossing a spontaneously diabetic strain (KK) with the
yellow obese strain (Ay) resulting in a mature-onset T2DM
phenotype68. Both DM and control normal glycemic siblings are
obese69. The NONcNZO10/LtJ mouse (NcZ10) is a polygenic model
of T2DMwith onset of DM in adulthood. The NcZ10 model requires
a chow content of 10e11% fat for higher penetrance (90e100%)59.
The TALLYHO/JngJ mouse (TH) has polygenic and maturity-onset
diabetes and has high penetrance in males59,70. A short list of
commonly available rodent models of T1DM and T2DM is pre-
sented in Table I. Readers are encouraged to review additional de-
tails in the references provided.
Animal studies investigating a link between DM and OA
There is an unfortunate paucity of quality research studies in
animal models of DM relevant to OA. A recent study using STZ-
induced T1DM in mice suggested the presence of cartilage dam-
age after 8 weeks of hyperglycemia, and showed elevated levels of
circulating AGEs73. Both abnormalities were ameliorated by the use
of the DM drug pioglitazone. The authors concluded that this drug
response implicated PPARg in this effect, but it was unclearwhether this was related to improvement of hyperglycemia or
PPARg inhibition. One valuable study applied the DIO model to the
C57Bl/6 strain andmade careful measures of physiological data and
histological OA outcomes74. This study combined a high fat diet
(60% by calorie) with the meniscal ligament injury model to induce
OA. Higher OA scores (increased joint degeneration) were found in
the mouse group receiving both high-fat diet and ligament injury.
However, since hyperglycemia was not established until the last
month of the experiment, it is unclear whether the hyper-
adiposity75 or the rising hyperglycemia was the driving factor for
greater OA progression. None the less, this is a valuable study
demonstrating acceleration of joint degeneration in association
with metabolic changes typically seen in DM patients.
Effects of DM and hyperglycemia on articular cartilage
Biomechanical properties of cartilage are highly inﬂuenced by
the composition of the extracellular matrix (ECM), and there is
some evidence that metabolic abnormalities associated with DM
alter cartilage ECM. Early studies in animal models of DM have
shown that decreased collagen production76 and increased pro-
teoglycan catabolism77 occurs in DM cartilage. Increased proteo-
glycan catabolism in DM animals has also been observed in non-
articular connective tissues78.
Effects of DM and hyperglycemia on bone
Studies showing delayed fracture healing in animals with DM
support the ample clinical data associating DM with bone abnor-
malities. The STZ mouse model demonstrates that poor diabetic
fracture healing is related to premature resorption of cartilage at
the fracture callus79, and that this was due to high levels of the
inﬂammatory cytokine TNFa in mice with DM80.
Effects of DM and hyperglycemia on tendons and ligaments
Animal models of DM fairly consistently show histologic and
biochemical abnormalities in tendons and ligaments, as well as less
well-characterized biomechanical changes, such as lower Young's
modulus and increased intra-substance failure81e83. Further,
several studies identify delayed tendon healing after injury in the
presence of DM84e87. These types of tendon and ligament abnor-
malities are known to promote OA88.
Effects of DM and hyperglycemia on synovium
The synovium of T1DM rats is abnormal and contains ﬁbrotic
tissue with higher amounts of type I collagen and lower quantities
of types III and V collagen89. Synovial pathology is a signiﬁcant
contributing factor to OA; early inﬂammatory changes in the
synovium may cause damage that then creates long-term produc-
tion of catabolic mediators90.
Potential mechanisms
Basic science studies have also identiﬁed some potential
mechanisms linked to DM-inﬂuenced end-organ joint damage.
Mediators such as hyperglycemia, AGEs, sorbitol, adipokines, and
cytokines act through oxidative, osmotic, and inﬂammatory
mechanisms to produce tissue damage (Table II). Further
complexity is added by the participation of similar molecular par-
ticipants in multiple catabolic pathways and the contributions of
similar metabolic derangements in obesity.
An increasing recognition of a key role for inﬂammation in both
OA98 and DM provides an important mechanistic link between
Table I
Commonly used rodent models for type 1 and type 2 DM
Model name* (short name) DM type Preferred control Advantages Disadvantages References
C57BL/6-Ins2Akita (Akita) T1DM Same strain background Available on other backgrounds Genetic background modulates DM phenotype 50,52e54
Streptozotocin (STZ) T1DM Same strain with vehicle treatment Economical
Can be used in most rodent strains and
other species
Drug toxicity 50,52,55
Alloxan monohydrate (Alloxan) T1DM Same strain with vehicle treatment Economical
Can be used in most rodent strains and
other species
Less efﬁcacious than STZ method 49,50,52
Biobreeding diabetes-prone rat (BBDP) T1DM Biobreeding diabetes-resistant rat (BBDR) Larger size (rat)
Polygenic
80e95% incidence
No sex bias
Will not develop DM in a pathogen-free environment 58,71
Diet-induced obesity (DIO) T2DM Same strain with vehicle treatment
(low fat chow)
Economical
Can model pre-diabetes state
Works well with C56BL/6 and NON strains
Mild or no hyperglycemia 51,64,66
C57BLKS-Leprdb (db/db) T2DM Heterozygous (þ/db) littermates One of the most studied models
No sex bias
Monogenic
Juvenile-onset
Early death
51,59,67
C57BLKS-Lepob (ob/ob) T2DM Heterozygous (þ/ob) littermates A well-studied model
No sex bias
Monogenic
Mild, short-term hyperglycemia
51,67
Zucker diabetic fatty rats (ZDF) T2DM ZDF lean Larger size (rat) Monogenic
No or mild hyperglycemia
DM in males only
51,67
KK.Cg-Ay/J (KKAy) T2DM Homozygous, non-diabetic siblings Polygenic T2DM
Maturity onset
Females have lower blood glucose levels 68
NONcNZO10/LtJ (NcZ10) T2DM NON/LtJ, SWR or FVB (Swiss-derived strains)
on low fat diet
Polygenic T2DM
Maturity onset
DM in males only
Requires high fat diet for high penetrance
59,60
TALLYHO/JngJ (TH) T2DM NON/LtJ, SWR, or FVB (Swiss-derived strains).
C57Bl/6 strain has also been used.
Polygenic T2DM
Maturity onset
High penetrance
DM in males only 59,70,72
* Where relevant, the most commonly used background strain is indicated although other backgrounds may be available. DM.
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Table II
Mechanisms present in diabetes that can damage joint tissues
Potential DM mechanisms Contributing pathways Examples of major mediators Examples of molecular participants References
Inﬂammation AGE/RAGE, innate immune pathways Cytokines, Adipokines, Reactive oxygen species MMPs, TLR 91,92
Oxidative stress Glucose transporters AGE/RAGE Reactive oxygen species GLUT, ATP, ADP 93e95
Osmotic stress Polyol pathway Sorbitol p38 MAPK 96,97
AGE ¼ advanced glycation end products, RAGE ¼ receptor for AGE, MMP ¼ matrix metalloproteinase, TLR ¼ toll-like receptors, GLUT ¼ glucose transporter family,
ATP ¼ adenosine triphosphate, ADP ¼ adenosine diphosphate, MAPK ¼ mitogen-activated protein kinase.
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exacerbated by the increased levels of inﬂammatory cytokines,
adipokines, and prostaglandins seen in DM tissues63. Signaling
through pathways of innate immunity, such as toll-like receptors,
also may produce inﬂammation in both DM92 and OA99.
In a hyperglycemic environment, there is increased production
of reactive oxygen species contributing to tissue damage. Cellular
transport of glucose becomes critical and may contribute to excess
oxidative stress. One group found that human OA chondrocytes
from donors aged 66 years cultured in high glucose are unable to
decrease GLUT1 protein or reduce glucose transport activity in
comparison with normal chondrocytes from young donors (age
28e35 years)94,100. They also found that high glucose conditions
favored production of oxidants and promoted matrix catabolism
which would accelerate OA. However, age and media osmolarity
were not controlled in those experiments101. The effects of high
glucose may be associated with impaired function of ATP-sensitive
Kþ channels which couple GLUT to intracellular ATP/ADP levels
and membrane potential102,103.
The AGE/RAGE system also plays a role in DM end-organ dam-
age through induction of inﬂammation and/or increased oxidative
stress. Collagen has an extraordinary low turnover in many con-
nective tissues and as such is prone to modiﬁcation by AGEs. The
formation of AGEs is accelerated by high tissue levels of glucose38.
AGEs signal through RAGE (receptor for AGEs) and other receptors
to produce various deleterious effects on chondrocytes including
inﬂammation and cytokine-mediated catabolism104e106 and have
been postulated to play a role in end-organ damage in DM38.
Further, AGE mediated cross-linking of collagen can alter a tissue's
biomechanical properties as shown for cartilage and tendon35e37.
Cross-linking by AGEs may also inhibit ECM turnover by restricting
access to proteolytic sites106. On the other hand, a recent study in
dogs suggests that an artiﬁcial increase in AGE levels alone using
repeated ribose injections did not accelerate OA in a mild injury
model107, but we know little about the effect of AGEs in the context
of the diabetic milieu. Thus, whether or how AGE's play a signiﬁcant
role in OA remains unclear.
In the polyol pathway, aldose reductase converts glucose to
sorbitol and galactose to galactitol. This mechanism is activated in
DM with excess polyols leading to cellular osmotic stress108.
Although not yet directly linked to OA, there is some evidence that
this pathway is activated in DM in intervertebral disc cartilage and
enhances matrix catabolism via p38 MAPK activation109.
Although not covered in detail in this review, additional DM-
relevant pathways have been proposed. For example, there is
considerable evidence that adipokines may induce inﬂammation
and have adverse effects on cartilage75,110 and tissue healing111.
Because altered adipokine levels are seen in obesity in both the
absence and presence of diabetes112, the contribution of adipokines
to OA in obese patients with DM will require further study. Alter-
ation in angiogenesis, autophagy, and apoptosis are also associated
with end-organ damage in OA58,113e116. Insulin receptors are pre-
sent on chondrocytes100, and thus, excess insulin as seen in T2DM
patients may also damage cartilage. In one study, PPARg down-
regulationwas shown to occur in articular chondrocytes exposed tohigh glucose media, but methodologic challenges warrant conﬁr-
mation of this ﬁnding73. Whether one or more pathways are
involved, which pathway is most relevant, and how molecular
mediators intersect multiple pathways will require additional
study.
Conclusions
In summary, increasing evidence from the clinic and the labo-
ratory supports an adverse effect of DM on the development,
severity, and therapeutic outcomes for OA. The etiology and clinical
manifestations of OA are complex, and currently we know little
about how the multiple mechanisms altered in DM may affect OA
that originates from different causes. Further, the clinical impact of
DM on OA may be underestimated by the high prevalence of un-
diagnosed diabetes3. A deeper understanding of OA in the setting of
DM could result in signiﬁcant improvements in clinical care. For
example, reducing OA-related joint pain may allow DM patients to
perform the exercise necessary for cardiovascular health. A full
appreciation of these disease interactions may also reduce the
increased medical costs associated with arthroplasty and other
surgeries in patients with comorbid DM20,21,32. To understand the
mechanisms through which DM contributes to OA, further work is
clearly necessary. Future studies of DM-inﬂuenced mechanisms
may shed light on the general mechanisms of OA pathogenesis and
result in more speciﬁc and effective therapies for all OA patients.
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